$AMBS NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) --

$AMBS NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (AMBS) in pre-clinical development advancing the orphan-drug designated therapeutic protein mesencephalic astrocyte-derived neurotrophic factor (MANF) as a disease-modifying treatment for orphan ophthalmological conditions, Glaucoma and Parkinson's disease, today announced the publication of a scientific article entitled "Poststroke delivery of MANF promotes functional recovery in rats" in the American Association for the Advancement of Science's (AAAS) open access journal Science Advances that describes positive effects of MANF in an animal model of post-stroke recovery. The work was published by researchers at the National Institute of Drug Abuse, the University of Helsinki and the Talinn University of Technology.

https://finance.yahoo.com/news/manf-therapeut...00144.html

Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!